FIELD: biotechnology.
SUBSTANCE: proposed allocated recombinant or purified antibody that specifically binds to the receptor of colony stimulating factor-1 (CSF-1R, CSF-1R), characterized by amino acid sequences of the variable domains. Also is provided nucleic acid encoding the antibody of the invention, vector, cell and method of producing the antibody. Furthermore, a pharmaceutical composition and the use of the antibodies and pharmaceutical composition of the invention as a medicament for the treatment of cancer, disease associated with increased osteoclast activity, inflammatory disease and rheumatoid arthritis, are described.
EFFECT: invention may find further application in the treatment of diseases associated with the CSF-1R.
19 cl, 32 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| CSF-1R ANTIBODY | 2009 |
|
RU2547586C2 |
| MACROPHAGE ACTIVATION MODULATION | 2012 |
|
RU2639553C2 |
| ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | 2012 |
|
RU2658603C2 |
| ANTIBODIES TO CANINE PD-1 | 2014 |
|
RU2761663C2 |
| HUMAN VISTA ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2746994C2 |
| ANTI-PTK7 ANTIBODY-DRUG CONJUGATES | 2015 |
|
RU2708075C2 |
| COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES | 2010 |
|
RU2569109C2 |
| TRISPECIFIC BINDING MOLECULES, WHICH SPECIFICALLY BIND ANTIGENS OF A VARIETY OF MALIGNANT TUMORS, AND METHODS OF USING THEM | 2015 |
|
RU2718692C2 |
| ANTIBODIES PRIMARILY BINDING TO EXTRACELLULAR DOMAIN 4 OF HUMAN CSF-1R, AND USING THEM | 2010 |
|
RU2565541C2 |
| MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
